linjc16/ctgov huggingface dataset:
Ventricular Arrhythmia Ablation With the Use of Non-Invasive ECG Imaging Technology

Study Overview
=================
Brief Summary
-----------------
Researchers are trying to determine if the use of software called VIVO, made by Catheter Precision, Inc. can shorten the length of time it takes to perform an ablation procedure for either premature ventricular contractions (PVCs) and ventricular tachycardia (VT).

Official Title
-----------------
Saving Time During Ventricular Arrhythmia Ablation With the Use of Non-Invasive ECG Imaging Technology

Conditions
-----------------
Premature Ventricular Contraction, Ventricular Tachycardia

Intervention / Treatment
-----------------
* Other: VIVO


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: At least 18 years of age Structurally normal heart Cardiac MRI/CT as part of standard of care Diagnosed with premature ventricular contractions or ventricular tachycardia and scheduled to undergo an ablation to treat these conditions Exclusion Criteria: Less than 18 years of age Structurally abnormal heart

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| No Intervention: Control Group<br>Subjects presenting for PVC/VT ablation will undergo ablation procedures using standard of care invasive electroanatomical mapping systems. | |
| Experimental: VIVO Arm<br>Subjects presenting for PVC/VT ablation, that have a previously acquired cardiac CT/MRI scan or are having a cardiac CT/MRI scan as per routine care, will undergo ablation procedures using VIVO, a novel, non-invasive mapping system. | Other: VIVO<br>* Non-invasive mapping system software product that combines patient-specific images (MRI or CT) of the torso and cardiac structures and a 3D image of the torso that identifies precise ECG lead placement to generate a 3D model of the patient's heart.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Standard of care invasive electroanatomical mapping system duration | Total amount of time for standard of care invasive mapping measured in minutes | Baseline | 
| VIVO non-invasive mapping system duration | Total amount of time for non-invasive mapping using VIVO measured in minutes | Baseline |
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions

Study Overview
=================
Brief Summary
-----------------
The objective of this study was to prove the bioequivalence of Valacyclovir Hydrochlorothiazide Caplet under fed conditions.

Official Title
-----------------
A Single Dose, 2-Period, 2-Treatment 2-Way Crossover Bioequivalency Study of Valacyclovir Caplets Under Fed Conditions

Conditions
-----------------
Herpes Zoster, Shingles, Genital Herpes

Intervention / Treatment
-----------------
* Drug: Valacyclovir Hydrochloride


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening Exclusion Criteria: Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to valacyclovir hydrochloride or any comparable or similar product.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Valacyclovir Hydrochloride|1000 mg caplet|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bioequivalence determined by statistical comparison Cmax |  | 8 days |
Exposure, Dose, Body Burden and Health Effects of Lead

Study Overview
=================
Brief Summary
-----------------
This is a study of the effects that lead has on the health of the central nervous system (for example, memory), peripheral nervous system (for example, sensation and strength in the hands and fingers), kidneys, blood pressure, and the blood forming system. A total of 803 lead workers and 135 persons without occupational lead exposure are being studied in South Korea. Lead in the body is being assessed by measurement of blood lead, chelatable lead (an estimate of lead in the tissues), and lead in bone. Subjects are tested three times each over three years. Several genetic factors are also being assessed for the role they play in the health effects of lead. These genes are known to differ among individuals. We are interested to know whether different forms of the same genes can modify the effect lead has on health.

Official Title
-----------------
Exposure, Dose, Body Burden and Health Effects of Lead

Conditions
-----------------
Lead Poisoning

Participation Criteria
=================
Eligibility Criteria
-----------------
Lead workers in South Korea in one of 26 specific lead-using facilities. Population controls in South Korea.

Ages Eligible for Study
-----------------
Minimum Age: 17 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
lead poisoning, central nervous system, peripheral nervous system, occupational health, genetic susceptibility
The Study of Slip Pulse Feature Extraction Method Based on the Image Processing Technology for Traditional Chinese Medicine

Study Overview
=================
Brief Summary
-----------------
The diagnoses processes of Traditional Chinese Medicine (TCM) focus on the following four main types of diagnoses methods consisting of inspection, listening and smelling, inquiry, and palpation. The most important one is palpation also called pulse diagnosis which is to measure wrist artery pulse by TCM doctor's fingers to detect patient's health state. The pulse diagnosis has three parts, namely 'Cun', 'Guan' and 'Chi', with the location. Wrist measurements correspond to different parts of the body's organs. However, the pulse information is analyzed by TCM doctor's pulse diagnoses process, which is picked only a single waveform from a long-term pulse measured process and often discarded the other waveforms contained in the same information, e.g. Slippery Pulse waveform. The research object of this project is to divide the TCM diagnosis patients into two groups, one is the Slippery Pulse group and the other is a Normal Pulse group, in which 30 cases are collected in each group. The purpose of this project will integrate the TCM doctor's experiences and standardize them in order to construct an effective Slippery Pulse diagnosis system. It could refine Slippery Pulse diagnoses processes and reduce their diagnoses loading by using the proposed approach during this project. Therefore, we could carry out the research on feature extraction method of Slippery Pulse based on the image processing technology. We could extract the pulse characteristics of Slippery Pulse automatically from the many measurement signals and improve the automatic judging ability of the current pulse instrument to the Slippery pulse waveform. Provide important pulse information to the TCM doctors as an important reference for clinical diagnoses.

Official Title
-----------------
The Study of Slip Pulse Feature Extraction Method Based on the Image Processing Technology for Traditional Chinese Medicine

Conditions
-----------------
Alippery Pulse

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Already sign test consent permit. More than 20-year-old. Exclusion Criteria: Can not accept acupuncture points stimulators. Allergic to acupuncture needles.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Slippery Pulse | The purpose of this project will integrate the TCM doctor's experiences and standardize them in order to construct an effective Slippery Pulse diagnosis system. | 30 minutes in duration. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Wrist artery pulse diagnosis instrument, TCM pulse diagnosis, Feature extraction
From Structural to Functional Characteristics of the Lumbar Multifidus in Low Back Pain

Study Overview
=================
Brief Summary
-----------------
To delineate the underlying mechanisms that contribute to chronic low back pain, by extending our knowledge on structural characteristics of the lumbar multifidus muscle using ultrasound muscle imaging, and by examining the association of structural features with functional performance, more precisely proprioceptive control.

Official Title
-----------------
From Structural to Functional Characteristics of the Lumbar Multifidus in Low Back Pain

Conditions
-----------------
Low Back Pain, Chronic Low Back Pain

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria for chronic low back pain group: Non-specific low back pain, during 3 or more months, without radicular leg pain Modified Low Back Pain Disability Questionnaire > 20% Indication for MRI of the lumbar spine No contra-indications for MRI Informed consent to participate Inclusion criteria for healthy control group: No history of low back pain needing medical treatment or resulting in limited activity level Any low back pain in the previous 3 months Informed consent to participate Exclusion criteria for all subjects: Pregnancy Previous trauma or surgery to spine, abdomen or pelvis Structural deformity (e.g. scoliosis) Neurological/neuromuscular/systemic disease Inability to lie prone for 20 minutes

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Low back pain group<br>Individuals with non-specific chronic low back pain | |
| Healthy control group<br>Healthy individuals without low back pain | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lumbar multifidus muscle volume measured by 3DfUS | in patients with chronic low back pain | immediately after inclusion in the study | 
| Lumbar multifidus muscle volume measured by MRI | in patients with chronic low back pain | immediately after inclusion in the study | 
| Cross-sectional area of the lumbar multifidus | measured by classic 2D-ultrasound in patients with chronic low back pain and healthy controls | immediately after inclusion in the study | 
| Thickness of the lumbar multifidus | measured by classic 2D-ultrasound in patients with chronic low back pain and healthy controls | immediately after inclusion in the study | 
| Proprioceptive postural control strategies in patients with low back pain with healthy controls | Mean center-of-pressure displacement in response to soleus muscle and/or multifidus muscle vibration (60 Hz, 0.5 mm) during upright standing on two support surfaces. | immediately after inclusion in the study |
Effect Evaluation of Early Exercise Training After Myocardial Infarction

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to evaluate the effect of early onset of exercise training (ET) after myocardial infarction (MI) in a randomized controlled trial. Usual care is to wait 4-6 weeks after onset of MI, and our hypotheses are that early ET will prevent a fall in VO2peak and contribute to better quality of life.

Detailed Description
-----------------
Exercise training is well documented as effective treatment for myocardial infarction(MI) patients. However, the long time effect of early onset is more unclear, and it is needed to provide knowledge about to which extend early onset of ET contribute to reduce risk factors, increase oxygen consumption and influence on quality of life. A RCT is conducted, 60 persons with recently MI is invited to participate. The subjects participating is hospitalised in St. Olavs Hospital. The participants are randomised to either a training group or a control group. The training group will be offered hospital out-patient group exercise training of moderate intensity twice a week for four weeks. The training is leaded by a physiotherapist. The control group will wait four weeks before both groups continue ET twice a week for 12 weeks (high intensity training).

Official Title
-----------------
Effect Evaluation of Early Exercise Training After Myocardial Infarction

Conditions
-----------------
Myocardial Infarction

Intervention / Treatment
-----------------
* Behavioral: exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Myocardiac infarction, 2 weeks ago over 18 years able to participate i exercise groups Exclusion Criteria: unstable angina heart failure failure to reach a maximal pretest drug abuse

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: exercise|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in maximal oxygen consumption |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| quality of life |  |  | 
| change in risk factors (smoking habits, physical activity) |  |  |
Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of the trial is to detect tumor microenvironment on Extensive Stage Small Cell Lung Cancer with simultaneous liver metastases who Treated with Atezolizumab plus Etoposide and Platinum Based Chemotherapy.

Official Title
-----------------
Tumor Microenvironment Surveillance on Simultaneous Liver Metastases Extensive Stage Small Cell Lung Cancer Who Treated With Atezolizumab Plus Etoposide and Platinum Based Chemotherapy

Conditions
-----------------
Extensive Stage Small Cell Lung Cancer

Intervention / Treatment
-----------------
* Drug: First line EC/EP+Atezolizumab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18， Extensive Stage Small Cell Lung Cancer Confirmed by Histopathology Treated with Atezolizumab plus Etoposide and Platinum Based Chemotherapy Exclusion Criteria: - Patients with contraindication of chemotherapy Pregnant or breast feeding women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: First line EC/EP+Atezolizumab|Etoposide (100mg/㎡) Carboplatin (AUC=4) Atezolizumab(1200mg) ivgtt, every 21 day|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PFS | Progression free survival | April 2019- July 2021 | 
| OS | Overall survival | April 2019- July 2021 |
Clinical and Molecular Study of CHARGE Syndrom

Study Overview
=================
Brief Summary
-----------------
Clinical description of a French cohort of patients with CHARGE syndrome. Search any phenotype-genotype correlation in typical, atypical or incomplete form of the syndrome Using Next generation Sequencing, try to identify other genes involved in this syndrome, as the CHD7 gene is involved in only 40-60% of cases

Conditions
-----------------
Development Abnormalies, Inclusion on Clinical Criteria of the Syndrome

Intervention / Treatment
-----------------
* Genetic: Blodd punction for genetic analysis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical criteria Major criteria: Ocular coloboma Chonamal atresia and/or cleft palate Semi-CircularCanals hypoplasia Minor criteria: Cranial nerves Hypothalamic-pituitary deficiency Internal or external ear malformation Cardiac, esophageal malformations Intellectual Deficiency Diagnosis criteria: Typical CHARGE: 3 major criteria or 2 major + 2 minor Partial CHARGE: 2 major + 1 minor Atypical CHARGE: 2 major without minor or 1 major + 2 minor Exclusion Criteria: Absent consentment for genetic analysis
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: No arm : descriptive study<br> | Genetic: Blodd punction for genetic analysis<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Description Clinical and molecular analysis of a French cohort CHARGE |  | 12 month | 
| Execution of the socio-adaptive scale, parental scale |  | 12 month | 
| Rate of mutations of CHD7 and / or type of mutations |  | 12 month | 
| analysis CHD7 gene from the patient's DNA |  | 12 month |
Effect of Time Shift of Transcranial Direct Current Stimulation (tDCS) for Treatment of Acute Tinnitus

Study Overview
=================
Brief Summary
-----------------
The treatment for patients with acute tinnitus consists of Methylprednisolone and hyperbaric oxygen therapy. For this study transcranial direct current stimulation (tDCS) was added to the protocol. The purpose is to determine the effect of the time shift of tDCS. Two conditions will be compared: tDCS simultaneously with the hyperbaric oxygen therapy or tDCS 3 weeks after the start of the tinnitus. An audiological testing will be performed at the day of admission, after 3 weeks, 6 weeks and 12 weeks.

Conditions
-----------------
Tinnitus

Intervention / Treatment
-----------------
* Other: transcranial direct current stimulation (tDCS)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age between 18 and 50 years presence of acute tinnitus or worsening of tinnitus caused by otogenic disease registration in UZA within 48 hours after start tinnitus VAS-score ≥ 4 ability to understand and sign informed consent Exclusion Criteria: history of epileptic seizures severe organic comorbidity psychiatric disorders or a history of psychiatric disorders with psychotic symptoms Pace maker pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Design Details

Allocation: Randomized
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: tDCS simultaneously with hyperbaric oxygen therapy<br> | Other: transcranial direct current stimulation (tDCS)<br> <br> |
| Active Comparator: tDCS 3 weeks after start tinnitus<br> | Other: transcranial direct current stimulation (tDCS)<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement of tinnitus | Tinnitus Questionnaire, Visual Analog Scale, Beck Depression Index, Hyperacusis questionnaire | 12 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hearing | Audiometry, Otoacoustic emissions, Tympanometry, Speech in noise | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
transcranial direct current stimulation, time shift